8/15/2022 7:25:00 AM
Arvinas Appoints Lisa Sinclair As SVP, Corporate Operations
8/1/2022 7:22:15 AM
Arvinas Appoints John Northcott As Chief Commercial Officer
5/9/2022 11:00:06 AM
Wedbush Is Lowering ARVINAS INC. (ARVN) FY22 Rev. Estimate To 128.7 M From 142.0 M
5/9/2022 10:59:38 AM
Wedbush Is Lowering ARVINAS INC. (ARVN) FY22 Estimate To -3.99 From -3.62
5/9/2022 10:59:23 AM
Wedbush Is Raising ARVINAS INC. (ARVN) Q3 22 Estimate To -0.93 From -0.94
5/9/2022 10:58:35 AM
Wedbush Downgrades ARVINAS INC. (ARVN) To Neutral From Outperform With $43 Down From $98 Price Target
3/1/2022 4:56:25 PM
Wedbush Is Cutting ARVINAS INC. (ARVN) FY22 Estimate To -3.62 From -1.84
3/1/2022 4:56:10 PM
Wedbush Is Lowering ARVINAS INC. (ARVN) Q4 22 Estimate To -1.01 From -0.55
3/1/2022 4:55:51 PM
Wedbush Is Lowering ARVINAS INC. (ARVN) Q3 22 Estimate To -0.94 From -0.49
3/1/2022 4:55:37 PM
Wedbush Is Cutting ARVINAS INC. (ARVN) Q2 22 Estimate To -0.85 From -0.41
3/1/2022 4:55:24 PM
Wedbush Is Lowering ARVINAS INC. (ARVN) Q1 22 Estimate To -0.82 From -0.39
3/1/2022 4:54:53 PM
Wedbush Reiterates ARVINAS INC. (ARVN) At Outperform With $98 Price Target
7/22/2021 8:18:11 AM
Arvinas And Pfizer Announce Global Collaboration To Develop PROTAC Protein Degrader ARV-471